An open-label, proof-of-concept, Phase 2 trial evaluating safety and efficacy of Otlertuzumab in combination with bendamustine in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL)
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Bendamustine (Primary) ; Otlertuzumab (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Proof of concept; Therapeutic Use
- 08 Jan 2018 Status changed from planning to recruiting, according to an Aptevo Therapeutics media release.
- 30 Nov 2017 New trial record
- 28 Nov 2017 According to an Aptevo Therapeutics media release, the company is planning to initiate this trial in the fourth quarter of 2017.